Search by Drug Name or NDC
NDC 00003-3641-11 EVOTAZ 300; 150 mg/1; mg/1 Details
EVOTAZ 300; 150 mg/1; mg/1
EVOTAZ is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by E.R. Squibb & Sons, L.L.C.. The primary component is ATAZANAVIR SULFATE; COBICISTAT.
MedlinePlus Drug Summary
The combination of atazanavir and cobicistat, along with other medications, is used to treat human immunodeficiency virus (HIV) infection in adults and children who weigh at least 77 lb (35 kg). Atazanavir is in a class of medications called protease inhibitors. It works by decreasing the amount of HIV in the blood. Cobicistat is in a class of medications called pharmacokinetic boosters. It works by increasing the amount of atazanavir in the body so that it can have a greater effect. Although atazanavir does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other life-style changes may decrease the risk of transmitting the HIV virus to other people.
Related Packages: 00003-3641-11Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Atazanavir and Cobicistat
Product Information
| NDC | 00003-3641 |
|---|---|
| Product ID | 0003-3641_36598a63-353c-4b23-83a1-46f225ea6765 |
| Associated GPIs | 12109902220330 |
| GCN Sequence Number | 073402 |
| GCN Sequence Number Description | atazanavir sulfate/cobicistat TABLET 300-150 MG ORAL |
| HIC3 | W5C |
| HIC3 Description | ANTIVIRALS, HIV-SPECIFIC, PROTEASE INHIBITORS |
| GCN | 37797 |
| HICL Sequence Number | 041722 |
| HICL Sequence Number Description | ATAZANAVIR SULFATE/COBICISTAT |
| Brand/Generic | Brand |
| Proprietary Name | EVOTAZ |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | atazanavir and cobicistat |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET |
| Route | ORAL |
| Active Ingredient Strength | 300; 150 |
| Active Ingredient Units | mg/1; mg/1 |
| Substance Name | ATAZANAVIR SULFATE; COBICISTAT |
| Labeler Name | E.R. Squibb & Sons, L.L.C. |
| Pharmaceutical Class | Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA206353 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00003-3641-11 (00003364111)
| NDC Package Code | 0003-3641-11 |
|---|---|
| Billing NDC | 00003364111 |
| Package | 30 TABLET in 1 BOTTLE (0003-3641-11) |
| Marketing Start Date | 2015-01-29 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 52.0974 |
| Pricing Unit | EA |
| Effective Date | 2022-11-23 |
| NDC Description | EVOTAZ 300 MG-150 MG TABLET |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 1 |
| Classification for Rate Setting | B |
| As of Date | 2022-11-23 |